Clinical Trial Detail

NCT ID NCT02910583
Title Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pharmacyclics LLC.
Indications

CLL/SLL

Therapies

Ibrutinib

Ibrutinib + Venetoclax

Age Groups: senior adult

No variant requirements are available.